Saturday, October 31, 2026

Boeing Stock Is 2% Up As Session Comes To An End On Monday

ViaNews Editorial Team

December 7, 2020

Boeing Stock Is 2% Up As Session Comes To An End On Monday
Shares of Boeing jumped 2.8% to $239.23 at 15:27 EST on Monday, following yesterday's downward trend. The New York Stock Exchange is falling 0.56% to $14,336.70, after four sequential sessions in a row of gains, on what as yet seems, a somewhat rough trend exchanging session today. Boeing's last close was $232.71, 47.81% under its 52-week high of $353.60.

News about Boeing today

Boeing upped to buy at UBS on narrowbody view. According to today's article on MarketWatch, "Boeing was upgraded to buy from neutral at UBS, which doubled its price target to $300 from $150. UBS said Boeing can get to 50 or more per month of production on the 737." American will fly the Boeing 737 max on 9 routes across the US come January after it returns to service this month - see the full list. According to today's article on Business Insider, "2021 is proving to be the year of the Max. American Airlines is regrowing its route network for the Boeing 737 Max in 2021 that will see more US travelers flying on the jet that's fresh from a 20-month grounding from the Federal Aviation Administration. "

Boeing's Sales

Boeing's sales growth is a negative 8.2% for the ongoing quarter and 0.9% for the next. The company's growth estimates for the present quarter and the next is 58.8% and 75.3%, respectively.

Boeing's Revenue

Year-on-year quarterly revenue growth declined by 29.2%, now sitting on 60.76B for the twelve trailing months.

Boeing's Stock Top and Bottom Yearly Value

Boeing's stock is valued at $239.23 at 15:27 EST, way under its 52-week high of $353.60 and way higher than its 52-week low of $89.00.

Boeing's Moving Average

Boeing's worth is way higher than its 50-day moving average of $184.62 and way above its 200-day moving average of $175.04.

Previous days news about Boeing

Ryanair chief puts rivals on notice with big Boeing jet purchase. According to Bloomberg Quint on Fri Dec 4, "Ryanair Holdings Plc has a plan to thunder back from the air travel slump, grabbing airport space while its weakened rivals are still in retreat." Boeing mulls equity sale, plans new cut to 787 dreamliner output. According to Bloomberg Quint on Fri Dec 4, "Boeing Co. is studying an equity sale and other ways to ease a debt burden that has soared to $61 billion this year amid the worst slump in aviation history."

In this story · Knowledge Files

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com